CA2875150C - Treatment of solid tumors using coenzyme q10 - Google Patents

Treatment of solid tumors using coenzyme q10 Download PDF

Info

Publication number
CA2875150C
CA2875150C CA2875150A CA2875150A CA2875150C CA 2875150 C CA2875150 C CA 2875150C CA 2875150 A CA2875150 A CA 2875150A CA 2875150 A CA2875150 A CA 2875150A CA 2875150 C CA2875150 C CA 2875150C
Authority
CA
Canada
Prior art keywords
coq10
dose
cancer
administration
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2875150A
Other languages
English (en)
French (fr)
Other versions
CA2875150A1 (en
Inventor
Niven Rajin Narain
John Patrick Mccook
Paul Y. Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BERG LLC
Original Assignee
BERG LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BERG LLC filed Critical BERG LLC
Priority to CA3090268A priority Critical patent/CA3090268A1/en
Publication of CA2875150A1 publication Critical patent/CA2875150A1/en
Application granted granted Critical
Publication of CA2875150C publication Critical patent/CA2875150C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2875150A 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10 Active CA2875150C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3090268A CA3090268A1 (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654245P 2012-06-01 2012-06-01
US61/654,245 2012-06-01
PCT/US2013/043785 WO2013181639A1 (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3090268A Division CA3090268A1 (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10

Publications (2)

Publication Number Publication Date
CA2875150A1 CA2875150A1 (en) 2013-12-05
CA2875150C true CA2875150C (en) 2020-10-27

Family

ID=49673946

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2875150A Active CA2875150C (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10
CA3090268A Abandoned CA3090268A1 (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3090268A Abandoned CA3090268A1 (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10

Country Status (16)

Country Link
US (3) US20140017317A1 (https=)
EP (1) EP2854528B8 (https=)
JP (3) JP6352905B2 (https=)
KR (2) KR102163948B1 (https=)
CN (1) CN104507308A (https=)
AU (2) AU2013267166A1 (https=)
BR (1) BR112014029954A2 (https=)
CA (2) CA2875150C (https=)
EA (1) EA032345B1 (https=)
ES (1) ES2761449T3 (https=)
IL (1) IL236008B (https=)
IN (1) IN2014DN10734A (https=)
MX (2) MX369768B (https=)
NZ (1) NZ702369A (https=)
SG (1) SG11201407880QA (https=)
WO (1) WO2013181639A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
EA032345B1 (ru) * 2012-06-01 2019-05-31 Берг Ллк Способ лечения рака с использованием кофермента q10
NZ713868A (en) * 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
US9996463B2 (en) * 2015-11-10 2018-06-12 International Business Machines Corporation Selection and placement of volumes in a storage system using stripes
WO2017087576A1 (en) * 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20170255565A1 (en) * 2016-03-02 2017-09-07 Intel Corporation Method and apparatus for providing a contiguously addressable memory region by remapping an address space
US20200093751A1 (en) * 2016-06-28 2020-03-26 Der-Yang Tien Chemoprotective/chemoactive nanodroplets and methods of use thereof
ES3017696T3 (en) 2017-05-17 2025-05-13 Bpgbio Inc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa
CA3239264A1 (en) * 2021-12-01 2023-06-08 Gambro Lundia Ab New dialysis fluid
WO2025087731A1 (en) * 2023-10-24 2025-05-01 Gambro Lundia Ab Compositions comprising insulin and ketones bodies to treat cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
WO2005048925A2 (en) * 2003-11-14 2005-06-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
KR101395370B1 (ko) * 2004-01-22 2014-05-14 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
US20080138326A1 (en) * 2006-12-06 2008-06-12 Kaneka Corporation Method for cancer treatment, carcinogenesis suppression or mitigation of adverse reactions of anticancer agents
MX337408B (es) 2007-03-22 2016-03-03 Berg Llc Formulaciones topicas que tienen biodisponibilidad aumentada.
US7732491B2 (en) * 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
WO2009073809A2 (en) 2007-12-04 2009-06-11 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
GB0913193D0 (en) 2009-07-29 2009-09-02 Johnson Matthey Plc Deoxygenation process
SG10202010355PA (en) * 2010-03-12 2020-11-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
EP2720680B1 (en) 2011-06-17 2020-02-12 Berg LLC Inhalable pharmaceutical compositions
EA032345B1 (ru) * 2012-06-01 2019-05-31 Берг Ллк Способ лечения рака с использованием кофермента q10

Also Published As

Publication number Publication date
MX2019013776A (es) 2020-01-30
EP2854528B8 (en) 2019-10-23
KR20150022932A (ko) 2015-03-04
IL236008A0 (en) 2015-02-01
MX2014014492A (es) 2015-05-12
MX369768B (es) 2019-11-21
EP2854528A1 (en) 2015-04-08
EA201492187A1 (ru) 2015-05-29
CN104507308A (zh) 2015-04-08
AU2017202567B2 (en) 2019-06-13
AU2017202567A1 (en) 2017-05-11
US20140017317A1 (en) 2014-01-16
IL236008B (en) 2018-08-30
JP6352905B2 (ja) 2018-07-04
EP2854528B1 (en) 2019-09-18
US20170216223A1 (en) 2017-08-03
CA2875150A1 (en) 2013-12-05
SG11201407880QA (en) 2014-12-30
ES2761449T3 (es) 2020-05-19
HK1208995A1 (en) 2016-03-24
EA032345B1 (ru) 2019-05-31
JP7225167B2 (ja) 2023-02-20
CA3090268A1 (en) 2013-12-05
WO2013181639A1 (en) 2013-12-05
AU2013267166A1 (en) 2014-12-18
WO2013181639A8 (en) 2014-12-31
KR20200118233A (ko) 2020-10-14
NZ702369A (en) 2016-12-23
JP2020183440A (ja) 2020-11-12
BR112014029954A2 (pt) 2017-06-27
IN2014DN10734A (https=) 2015-09-04
JP2015518056A (ja) 2015-06-25
KR102163948B1 (ko) 2020-10-12
JP2018168164A (ja) 2018-11-01
EP2854528A4 (en) 2016-03-09
US20220096399A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
US20220096399A1 (en) Methods of treatment of solid tumors using coenzyme q10
US20210369645A1 (en) Methods for the treatment of cancer using coenzyme q10 combination therapies
US11452699B2 (en) Method of treating or preventing tumors of the central nervous system
US20200330400A1 (en) Methods for the treatment of cancer using coenzyme q10 and fatty acid metabolism inhibitors
HK1208995B (en) Treatment of solid tumors using coenzyme q10

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180531

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241118

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241118